Top Chinese Think Tank Visits Boston for Study on Health Information Technology
28 November 2018
Earlier this month, Boston Healthcare Associates hosted a delegation from the China Development Research Foundation (CDRF), a public foundation initiated by the Development Research Center of the State Council of the People’s Republic of China, with the mission to provide policy research support for policy making on a national level.
CDRF supports evidence-based policy research, leadership training, high-level forums and symposiums to promote economic cooperation and development, and the promotion of responsible public policy.
The delegation visited Boston to learn more about the role that Health Information Technology (HIT) plays in the healthcare system, how its development has progressed, and future opportunities for improving efficiency and quality of care. Boston, as a global leader in the healthcare and life sciences industry, and home to some of the world’s leading hospitals and community health centers, health IT, and digital health companies, was chosen as one of the field study sites.
The delegation heard from innovative leaders in the HIT space from Partner’s Healthcare, Watson Health, and Harvard Pilgrim Healthcare on day one of the trip during a half day Forum at the Royal Sonesta in Cambridge. Speakers provided the delegation with an in-depth overview of the application of health information technology in healthcare delivery and management.
While in Boston, the delegation also visited and toured Boston Children’s Hospital, the MIT-IBM Watson AI Lab, and Massachusetts General Hospital.
With the Chinese government seeking to improve efficiency and quality of healthcare services and health insurance, especially at the community level, the exchange of information between innovative health organizations is timely.
Boston Healthcare has a deep understanding of the evolving value and access landscape in China. Please contact us for more information.
From November 1, 2016 to September 1, 2019, the Italian Medicines Agency, AIFA evaluated a total of 166 Dossiers - 28 were related to orphan drugs, 56 to new active substances, 57 to extensions of indications for drugs already reimbursed, and 25 to other types of negotiations.
The field of DTx has gained traction over the last couple of years, with FDA approvals/clearances, the founding of a DTx specialty society, large-scale acquisitions of DTx firms, pharma investments in DTx, and pharma co-development deals, amongst other key developments.